Open Access Repository

Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study


Downloads per month over past year

Robman, L, Guymer, R, Woods, R, Ward, S, Wolfe, R, Phung, J, Hodgson, L, Makeyeva, G, Aung, KZ, Gilbert, T, Lockery, J, Le-Pham, Y-A, Orchard, S, Storey, E, Abhayaratna, W, Reid, D, Ernst, ME, Nelson, M ORCID: 0000-0001-9941-7161, Reid, C and McNeil, J 2017 , 'Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study' , Contemporary Clinical Trials Communications, vol. 6 , pp. 105-114 , doi: 10.1016/j.conctc.2017.03.005.

116517 Journal ...pdf | Download (150kB)

| Preview


Purpose: Although aspirin therapy is used widely in older adults for prevention of cardiovasculardisease, its impact on the incidence, progression and severity of age-related macular degeneration(AMD) is uncertain. The effect of low-dose aspirin on the course of AMD will be evaluated in thisclinical trial.Design: A sub-study of the ‘ASPirin in Reducing Events in the Elderly’ (ASPREE) trial, ASPREE-AMD is a5-year follow-up double-blind, placebo-controlled, randomized trial of the effect of 100 mg daily aspirinon the course of AMD in 5000 subjects aged 70 years or older, with normal cognitive function andwithout cardiovascular disease at baseline. Non-mydriatic fundus photography will be performed atbaseline, 3-year and 5-year follow-up to determine AMD status.Primary outcome measures: The incidence and progression of AMD. Exploratory analyses will determinewhether aspirin affects the risk of retinal hemorrhage in late AMD, and whether other factors,such as genotype, systemic disease, inflammatory biomarkers, influence the effect of aspirin on AMD.Conclusion: The study findings will be of significant clinical and public interest due to a potential toidentify a possible low cost therapy for preventing AMD worldwide and to determine risk/benefitbalance of the aspirin usage by the AMD-affected elderly. The ASPREE-AMD study provides a uniqueopportunity to determine the effect of aspirin on AMD incidence and progression, by adding retinalimaging to an ongoing, large-scale primary prevention randomized clinical trial.

Item Type: Article
Authors/Creators:Robman, L and Guymer, R and Woods, R and Ward, S and Wolfe, R and Phung, J and Hodgson, L and Makeyeva, G and Aung, KZ and Gilbert, T and Lockery, J and Le-Pham, Y-A and Orchard, S and Storey, E and Abhayaratna, W and Reid, D and Ernst, ME and Nelson, M and Reid, C and McNeil, J
Keywords: Age-related macular degeneration, AMD, aspirin, incidence, progression, randomized controlled trial
Journal or Publication Title: Contemporary Clinical Trials Communications
Publisher: Elsevier Inc.
ISSN: 2451-8654
DOI / ID Number: 10.1016/j.conctc.2017.03.005
Copyright Information:

© 2017 The Authors. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page